NCT06837454 French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
| NCT ID | NCT06837454 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sanofi |
| Condition | Atopic Dermatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-02-04 |
| Primary Completion | 2027-05-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2025-02-04 with a primary completion date of 2027-05-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD). This study will be proposed to a sample of French dermatologists experienced in the management of AD, practicing in hospital centers and/or office-based dermatologists. The study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. Each patient will be followed-up in routine care setting for 1 year.
Eligibility Criteria
Inclusion Criteria: * Signed informed consent form. * Patient with moderate to severe AD according to the Investigator's judgment and 1. Patient eligible to systemic treatment as Atopic Dermatitis Control Tool (ADCT) more than or equal to (≥) 7 and/or use topical corticosteroids (TCS) more than (\>) 90 gram (g)/month and/or TCS are not advisable. or 2. Patient currently under systemic treatment. * Able to understand and complete study-related questionnaires. Exclusion Criteria: * Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments * Patient receiving systemic therapy only for a disease other than AD. * Patient participating in any interventional clinical trial at the time of enrolment. * Patient is under tutorship or curatorship; patient under safeguard of justice or deprived of his/her liberty by an administrative or court decision The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contact & Investigator
Trial Transparency email recommended (Toll free for US & Canada)
✉ Contact-US@sanofi.com📞 800-633-1610
Frequently Asked Questions
Who can join the NCT06837454 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06837454 currently recruiting?
Yes, NCT06837454 is actively recruiting participants. Contact the research team at Contact-US@sanofi.com for enrollment information.
Where is the NCT06837454 trial being conducted?
This trial is being conducted at Aix-en-Provence, France, Amiens, France, Angers, France, Angers, France and 11 additional locations.
Who is sponsoring the NCT06837454 clinical trial?
NCT06837454 is sponsored by Sanofi. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.